Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30182933 | 1.00 | MDM4 (0.51) | MDM4TP53CTSLCTSSCTSK | |
| SCHEMBL29511478 | 1.00 | MDM4 (0.51) | MDM4TP53CTSLCTSSCTSK | |
| SCHEMBL6790172 | 1.00 | MDM4 (0.51) | MDM4TP53CTSLCTSSCTSK | |
| SCHEMBL799761 | 1.00 | MDM4 (0.51) | MDM4TP53CTSLCTSSCTSK | |
| SCHEMBL29444635 | 1.00 | MDM4 (0.51) | MDM4TP53CTSLCTSSCTSK | |
| SCHEMBL6019567 | 0.87 | CTSS (0.68) | CTSLCTSSCTSK | |
| SCHEMBL4667145 | 0.86 | CASP3 (0.49) | MDM4TP53CTSLCTSSCTSK | |
| SCHEMBL4667142 | 0.86 | CASP3 (0.49) | MDM4TP53CTSLCTSSCTSK | |
| SCHEMBL6019561 | 0.84 | CTSL (0.49) | MDM4TP53CTSLCTSSCTSK | |
| SCHEMBL6019553 | 0.84 | CTSL (0.53) | MDM4TP53CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20200392197-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800826-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190071483-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2019-03-07 | — | — | US | disclosed |
| US-9150899-B2 | Identification of compounds modifying a cellular response | 2CUREX (DK) | 2015-10-06 | — | — | US | disclosed |
| US-20130123140-A1 | IDENTIFICATION OF COMPOUNDS MODIFYING A CELLULAR RESPONSE | 2CUREX (DK) | 2013-05-16 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20090239755-A1 | Identification of Compounds Modifying A Cellular Response | 2CUREX (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| EP-2018859-A1 | Arylmethylene substituted N-acyl-beta-amino alcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-20080194524-A1 | Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof | JERINI AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1703912-A1 | COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | Jerini AG (DE) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005063259-A1 | COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | JERINI AG (DE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071483-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | GLP1R, GCG, GCGR | MDM4 3145/4885TP53 3566/4885CTSL 568/4885 |
| US-20080194524-A1 | Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof | CCNB1, CCNB2, CCNA1 | MDM4 1047/4885TP53 99/4885CTSL 2760/4885 |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | MDM4 3145/4885TP53 3566/4885CTSL 568/4885 |
| US-20200392197-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | GLP1R, GCG, GCGR | MDM4 3145/4885TP53 3566/4885CTSL 568/4885 |
| US-20090239755-A1 | Identification of Compounds Modifying A Cellular Response | MCL1, PMAIP1, CDC37 | MDM4 169/4885TP53 18/4885CTSL 68/4885 |
| US-10800826-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | MDM4 3145/4885TP53 3566/4885CTSL 568/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM4 1060/4885TP53 573/4885CTSL 499/4885 |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | MDM4 4701/4885TP53 4005/4885CTSL 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.